Target intelligence / Profile preview

Sarcoma antigen 4 pseudogene (SAGE4P)

Target: SAGE4P
Molecular classification: Pseudogene, Non-coding RNA

Overview

Sarcoma antigen 4 pseudogene (SAGE4P) is a genomic sequence that shares high similarity with the coding gene for sarcoma antigen 4, but contains mutations (such as frameshifts or premature stop codons) that prevent it from encoding a functional protein. Pseudogenes were long considered "junk DNA," but recent studies indicate many may have biological roles in gene expression regulation, including potential involvement in cancer through regulatory RNA mechanisms. SAGE4P itself is not a therapeutic target and has not been described as functionally relevant in disease or drug response.

Other names: SAR antigen 4 pseudogeneSAGE4PSarcoma antigen 4, pseudogene

Mechanism of action

None directly; as no drugs target this pseudogene.

Biological functions

Pseudogenes are typically non-functional in terms of coding capacity, but many may have regulatory roles, such as acting as competing endogenous RNAs (ceRNAs) or influencing gene expression through sequence similarity or transcriptional interference

Disease associations

Cancer (pseudogenes generally have roles as biomarkers or may participate in regulatory networks in cancer, but direct disease involvement requires evidence for the specific pseudogene)

Safety considerations

Not applicable; no safety concerns are associated directly with pseudogenes as drug targets, since they are not targeted by drugs.

Biomarkers

Pseudogene expression signatures can serve as prognostic or diagnostic biomarkers, including in cancer subtypes like osteosarcoma or glioma if the specific pseudogene is validated for such use. No indication that SAGE4P itself is validated or used clinically as a biomarker.

Beyond the preview

Go deeper on Sarcoma antigen 4 pseudogene (SAGE4P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sarcoma antigen 4 pseudogene (SAGE4P).

Explore the full profile